ArticleClinical pharmacology in drug development2019
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
Article in Clinical pharmacology in drug development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04280289 (CBD Cannabis Extract), which is not on this map. Cited by 99 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CBD Cannabis Extract: Pharmacokinetic Studies
Who cites it
99 citing papers in PubMed, 13 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.European journal of drug metabolism and pharmacokinetics · 2026Pooled it
- [Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol].Revista de neurologia · 2024Guideline
- Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis.Cannabis and cannabinoid research · 2024Pooled it
- Evaluation of potential drug-drug interactions with medical cannabis.Clinical and translational science · 2024Pooled it
- Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, andFrontiers in pharmacology · 2024Pooled it
- Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review.Current neuropharmacology · 2023Pooled it
- Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies.Pharmacotherapy · 2021Pooled it
- Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.Acta neurologica Scandinavica · 2021Pooled it
- Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.Acta neurologica Scandinavica · 2020Pooled it
- Pooled it
- Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.CNS drugs · 2020Pooled it
- Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.Clinical pharmacology and therapeutics · 2026Trial
- A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women.Scientific reports · 2025Trial
- Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.Epilepsia · 2021Trial
- A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.Journal of clinical pharmacology · 2020Trial
- A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Trial
- Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.JAMA neurology · 2020Trial
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial investigated the impact of cannabidiol on steady-state pharmacokinetics of clobazam (and N-desmethylclobazam), stiripentol, and valproate; the reciprocal effect of clobazam, stiripentol, and valproate on cannabidiol and its major metabolites (7-hydroxy-cannabidiol [7-OH-CBD] and 7-carboxy-cannabidiol [7-COOH-CBD]); and cannabidiol safety and tolerability when coadministered with each antiepileptic drug. Concomitant cannabidiol had little effect on clobazam exposure (maximum concentration [C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.